Italy· 042925026
STIVARGA*3x28 cpr rivestite 40 mg flacone
A regorafenib product containing regorafenib, registered in Italy by BAYER AG, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Regorafenib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX05 (regorafenib), each read from that country’s own register.
- This record: Italy
- 9 of them publish a price we can compare per daily dose
Regorafenib · ATC L01EX05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of regorafenib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- Italy: $140.25 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Regorafenib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- IT Italy$140.25
- CH Switzerland$139.52
The record
At a glance
- Active substance
- Regorafenib
- Manufacturer
- BAYER AG
- Country
- Italy (IT)
- ATC code
- L01EX05
- ATC class
- Regorafenib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic042925026STIVARGA*3x28 cpr rivestite 40 mg flaconeEUR 3449.34
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
248 interactions on record for regorafenib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regorafenib · interactions on record
248 records
- 116 severe
- 125 moderate
- 7 minor
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regorafenib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandStivargaParanova Oy
- CzechiaSTIVARGABayer AG, Leverkusen
- United KingdomStivarga 40mg tabletsBayer Plc
- SpainSTIVARGA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULABayer Ag
- FranceSTIVARGA 40 mg, comprimé pelliculéBAYER AG (ALLEMAGNE)
- IrelandStivarga 40 mg film-coated tabletsBayer Pharma AG
- IcelandStivargaBayer AG*
- NetherlandsStivarga 40 mg, filmomhulde tabletBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Stivarga
- Liechtenstein · Stivarga
- Norway · Stivarga
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5b621a84-118f-4481-8339-8c5463b75b22 GET /v1/drugs/5b621a84-118f-4481-8339-8c5463b75b22?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 3449.34,
"source": "aifa",
"currency": "EUR",
"strength": "REGORAFENIB 40MG 84 UNITA' USO ORALE",
"substance": "Regorafenib",
"equivalence_group": "HAD",
"transparency_flag": null
}See everything about regorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.